Technology stocks: choose between chip cycles and services cash flow

Synopsys sells design automation software and semiconductor IP, tools used to design and verify chips and complex systems. Its fiscal Q3 2026 Design Automation revenue was $2.003 billion, compared with $473.8 million for Design IP; Design Automation includes Ansys, so the larger segment also makes integration central to the growth case. The company-page figures show 15.0% revenue growth, the group’s highest, alongside an 87.9x trailing P/E and 2.8% trailing FCF yield.

What breaks itThe report notes that nine-month Design IP revenue was $1.335 billion, below $1.345 billion a year earlier, while acquired-intangible amortization and other adjustments widen the gap between GAAP and non-GAAP profitability. Elevated risk and $10.6 billion of net debt leave less room for integration or growth to disappoint.

Full report: Synopsys stock: buyback headlines meet a valuation that needs growth (8 Oct 2026)

Teradyne sells automated test equipment for semiconductors and electronics and also makes collaborative and mobile robots. Semiconductor Test generated $1,122 million of Q2 2026 revenue, far more than Product Test at $107 million or Robotics at $100 million. The table pairs 13.1% revenue growth and a 20.4% operating margin with a 1.2% trailing FCF yield and Elevated risk.

What breaks itThe report found that Q2 GAAP operating margin was 32.9%, down from 36.9% in Q1 even as revenue rose. Its specific vulnerability is cyclical: if AI-related or memory-testing demand cools, earnings expectations built around recent sales strength could reset quickly.

Full report: Teradyne stock: record revenue leaves little room for a stumble (7 Oct 2026)

Accenture sells consulting and managed services, with revenue from project work and ongoing operational support. Its table figures show 7.3% revenue growth, a 14.7% operating margin and a 10.4% trailing FCF yield; its 15.7x trailing P/E is far below the chip-focused names in this comparison. The latest filing discussed in the report showed Q3 FY2026 revenue, diluted EPS and operating income all higher year over year, though that filing covered the quarter ended May 31, 2026.

What breaks itClient spending determines how much work is available, and Accenture must staff and deliver projects to turn demand into revenue. The report also records $3.004 billion of net purchases of businesses and investments in the first nine months of fiscal 2026, so cash flow after property investment did not represent cash left after every capital-allocation choice.

Full report: Accenture stock falls 6.3% as the reason for today’s move stays unclear (5 Oct 2026)

Cognizant earns revenue from consulting, implementation and managed services, including work for financial institutions and healthcare organizations. The table shows a 12.4x trailing P/E, 9.1% trailing FCF yield, 17.2% ROIC and negative $1.4 billion net debt, alongside 6.9% revenue growth. Its Q2 2026 results were mixed: revenue rose 4.5% year over year to $5.481 billion, while quarterly bookings fell 6%.

What breaks itGrowth was concentrated in Financial Services: the report says that segment grew 12.0% in Q2, while Health Sciences grew 1.4% and the other two segments grew around 1% to 2%. Bookings do not guarantee near-term revenue, and most contracts can be terminated on short notice.

Full report: Cognizant stock falls 3.9% with no clear new catalyst (5 Oct 2026)

Synopsys and Teradyne fit readers who want direct exposure to chip-design demand or semiconductor testing and can accept elevated risk, acquisition complexity or cyclical earnings. Accenture suits readers who prefer a larger consulting and managed-services business with the strongest FCF yield in this group; Cognizant may fit those drawn to a lower trailing P/E and higher ROIC, provided they accept uneven segment growth and booking volatility. These are different business and risk profiles, not a ranking by upside; all four are classified as fairly valued in the table.